Frederick Munschauer, MD
At the 2016 CMSC Annual Meeting, Dr. Munschauer discussed the results of three studies that used real-world data to look at relapse rates, outpatients resource use, and costs related to patients taking subcutaneous interferon beta-1a as compared with other MS therapies.
MS drugs in Medicare Part D: Higher tiers, less coverage, more prior authorizations
VIDEO: AAN MS guidelines aim to help clinicians weigh expanding drug choicesPublish date: April 24, 2018
Ari Green, MDPublish date: April 5, 2018
VIDEO: Teriflunomide and dimethyl fumarate are comparable in relapsing-remitting MSPublish date: February 9, 2018
Adil Harroud, MDPublish date: February 9, 2018
Immunopathogenesis, diagnosis, and treatment of MS